Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Yi Jiun Su; Anne Marijn Kramer; Mark P. Hamilton; Neha Agarwal; Hrishikesh K. Srinagesh; John H. Baird; Bita Sahaf; Adam Kuo; Zachary J. Ehlinger; Moksha H. Desai; Skyler P. Rietberg; Ramya Tunuguntla; Shabnum Patel; Harshini Chinnasamy; Nikolaos Gkitsas-Long; Dorota D. Klysz; Annie Kathleen Brown; Sushma Bharadwaj; Saurabh Dahiya; Melody Smith; Lori Muffly; Crystal L. Mackall; Zinaida Good; Steven A. Feldman; David B. Miklos; Matthew J. Frank

doi:10.1158/2159-8290.CD-24-1071

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Yi Jiun Su
, Anne Marijn Kramer
, Mark P. Hamilton
, Neha Agarwal
, Hrishikesh K. Srinagesh
, John H. Baird
, Bita Sahaf
, Adam Kuo
, Zachary J. Ehlinger
, Moksha H. Desai
, Skyler P. Rietberg
, Ramya Tunuguntla
, Shabnum Patel
, Harshini Chinnasamy
, Nikolaos Gkitsas-Long
, Dorota D. Klysz
, Annie Kathleen Brown
, Sushma Bharadwaj
, Saurabh Dahiya
, Melody Smith

Lori Muffly, Crystal L. Mackall, Zinaida Good, Steven A. Feldman, David B. Miklos, Matthew J. Frank^*

^*Corresponding author for this work

Stanford University
Chang Gung Memorial Hospital
City of Hope National Med Center
Parker Institute for Cancer Immunotherapy

Research output: Contribution to journal › Journal Article › peer-review

2 Scopus citations

Abstract

Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

Original language	English
Pages (from-to)	733-747
Number of pages	15
Journal	Cancer Discovery
Volume	15
Issue number	4
DOIs	https://doi.org/10.1158/2159-8290.CD-24-1071
State	Published - 02 04 2025
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 9 Industry, Innovation, and Infrastructure

Keywords

Humans
Immunotherapy, Adoptive/methods
Antigens, CD19/immunology
Receptors, Chimeric Antigen/immunology
Sialic Acid Binding Ig-like Lectin 2/immunology
Male
Treatment Outcome
Female
Middle Aged
Receptors, Antigen, T-Cell
Leukemia, Lymphocytic, Chronic, B-Cell/therapy
Aged
Leukapheresis

Access to Document

10.1158/2159-8290.CD-24-1071

Cite this

Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, S., Chinnasamy, H., Gkitsas-Long, N., Klysz, D. D., Brown, A. K., Bharadwaj, S., Dahiya, S., ... Frank, M. J. (2025). Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL. Cancer Discovery, 15(4), 733-747. https://doi.org/10.1158/2159-8290.CD-24-1071

@article{140cd351b554496eb1b4c96a84722b2a,

title = "Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL",

abstract = "Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ na{\"i}ve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.",

keywords = "Humans, Immunotherapy, Adoptive/methods, Antigens, CD19/immunology, Receptors, Chimeric Antigen/immunology, Sialic Acid Binding Ig-like Lectin 2/immunology, Male, Treatment Outcome, Female, Middle Aged, Receptors, Antigen, T-Cell, Leukemia, Lymphocytic, Chronic, B-Cell/therapy, Aged, Leukapheresis",

author = "Su, \{Yi Jiun\} and Kramer, \{Anne Marijn\} and Hamilton, \{Mark P.\} and Neha Agarwal and Srinagesh, \{Hrishikesh K.\} and Baird, \{John H.\} and Bita Sahaf and Adam Kuo and Ehlinger, \{Zachary J.\} and Desai, \{Moksha H.\} and Rietberg, \{Skyler P.\} and Ramya Tunuguntla and Shabnum Patel and Harshini Chinnasamy and Nikolaos Gkitsas-Long and Klysz, \{Dorota D.\} and Brown, \{Annie Kathleen\} and Sushma Bharadwaj and Saurabh Dahiya and Melody Smith and Lori Muffly and Mackall, \{Crystal L.\} and Zinaida Good and Feldman, \{Steven A.\} and Miklos, \{David B.\} and Frank, \{Matthew J.\}",

note = "{\textcopyright}2025 American Association for Cancer Research.",

year = "2025",

month = apr,

day = "2",

doi = "10.1158/2159-8290.CD-24-1071",

language = "英语",

volume = "15",

pages = "733--747",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

Su, YJ, Kramer, AM, Hamilton, MP, Agarwal, N, Srinagesh, HK, Baird, JH, Sahaf, B, Kuo, A, Ehlinger, ZJ, Desai, MH, Rietberg, SP, Tunuguntla, R, Patel, S, Chinnasamy, H, Gkitsas-Long, N, Klysz, DD, Brown, AK, Bharadwaj, S, Dahiya, S, Smith, M, Muffly, L, Mackall, CL, Good, Z, Feldman, SA, Miklos, DB & Frank, MJ 2025, 'Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL', Cancer Discovery, vol. 15, no. 4, pp. 733-747. https://doi.org/10.1158/2159-8290.CD-24-1071

TY - JOUR

T1 - Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

AU - Su, Yi Jiun

AU - Kramer, Anne Marijn

AU - Hamilton, Mark P.

AU - Agarwal, Neha

AU - Srinagesh, Hrishikesh K.

AU - Baird, John H.

AU - Sahaf, Bita

AU - Kuo, Adam

AU - Ehlinger, Zachary J.

AU - Desai, Moksha H.

AU - Rietberg, Skyler P.

AU - Tunuguntla, Ramya

AU - Patel, Shabnum

AU - Chinnasamy, Harshini

AU - Gkitsas-Long, Nikolaos

AU - Klysz, Dorota D.

AU - Brown, Annie Kathleen

AU - Bharadwaj, Sushma

AU - Dahiya, Saurabh

AU - Smith, Melody

AU - Muffly, Lori

AU - Mackall, Crystal L.

AU - Good, Zinaida

AU - Feldman, Steven A.

AU - Miklos, David B.

AU - Frank, Matthew J.

PY - 2025/4/2

Y1 - 2025/4/2

N2 - Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

AB - Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

KW - Humans

KW - Immunotherapy, Adoptive/methods

KW - Antigens, CD19/immunology

KW - Receptors, Chimeric Antigen/immunology

KW - Sialic Acid Binding Ig-like Lectin 2/immunology

KW - Male

KW - Treatment Outcome

KW - Female

KW - Middle Aged

KW - Receptors, Antigen, T-Cell

KW - Leukemia, Lymphocytic, Chronic, B-Cell/therapy

KW - Aged

KW - Leukapheresis

UR - https://www.scopus.com/pages/publications/105002790817

U2 - 10.1158/2159-8290.CD-24-1071

DO - 10.1158/2159-8290.CD-24-1071

M3 - 文章

C2 - 39775812

AN - SCOPUS:105002790817

SN - 2159-8274

VL - 15

SP - 733

EP - 747

JO - Cancer Discovery

JF - Cancer Discovery

IS - 4

ER -

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this